Myasthenia Gravis Panel 2
Myasthenia Gravis Panel 2 measures acetylcholine receptor (AChR) binding, blocking, and modulating antibodies to detect autoimmune attack on neuromuscular junctions. Nearly 80% of generalized MG patients have detectable AChR antibodies. The panel aids in diagnosing muscle weakness, fatigability, differentiating MG subtypes, and guiding treatment decisions in neuromuscular autoimmune disease settings.
- $588.74
- $373.95
- Save: 36.48%
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Anti-striated Muscle Antibody
Acetylcholine Receptor
Acetylcholine Receptor
Acetylcholine Receptor
The Myasthenia Gravis Panel 2 test contains 1 test with 3 biomarkers .
Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody.
Acetylcholine Receptor Binding Antibody
Acetylcholine Receptor Blocking Antibody
Acetylcholine Receptor Modulating Antibody